Wantstats
Company ProfilePremium

Guerbet

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Guerbet - Healthcare showcase

Year Founded & Workforce

1926

2,800 Employees

Industry

Healthcare

Services

Embolization Particle
G

Guerbet Employee Contacts

48 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Guerbet Overview

Company Headquarters: Villepinte, France

Founded: 1926

Workforce: ~2,800

Company Working: Guerbet operates in the medical imaging field, offering a wide range of pharmaceutical products, medical devices, digital and artificial intelligence solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. Guerbet is continuously incorporating innovation in its products with research and development centers in France, Israel, and the US. The company operates in two reportable segments, diagnostic imaging, and intervention imaging.

Strategy

Guerbet focuses on developing innovative therapies through partnerships, joint ventures, and agreements. The company plans to enhance its strengths by emphasizing the expansion of its business by increasing its focus on embolization market trends in the coming years. Also, with the acquisition of Occlugel, the company aims to capture maximum market share in the embolization particle market in the near future.

Company Snapshot

$807.1M

Revenue

2,800

Employees

1926

Founded

Villepinte, France

Headquarters

SWOT Analysis

Strengths

  • Joint ventures with public and private organizations
  • Renowned customer base
  • Customer centric medical products
  • Mergers and acquisitions

Weaknesses

  • Limited product line
  • Limited focus on Oceanic countries

Opportunities

  • Expansion in untapped regions
  • Focus on expanding products offering

Threats

  • Legal risks
  • Volatile foreign exchange rates

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
June 2019Product ApprovalGuerbet’s product, Lipiodol Ultra Fluid, was approved in Switzerland and India for a new indication, chemoembolization (cTACE) of tumors in adults with known intermediate-stage hepatocellular carcinoma (HCC).
April 2018AcquisitionGuerbet acquired a laboratory-stage technology developed by Occlugel, a French company specialized in the research and development of microspheres used in embolization

Product Offering

  • Guerbet
    • Embolization Particle

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 807.1 Mn in 2017 to USD 816.9 Mn in 2019.
Guerbet — By Business Segment
Series (USD Mn)201720182019
Sales807.1789.6816.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →